NCT01688882 - Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

Bullous Pemphigoid

Interventions

DRUG

QGE031

QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.

DRUG

Placebo

Placebo will be used to control for normal variability in disease severity.

Trial Locations (9)

Novartis Investigative Site, Taipei

Novartis Investigative Site, Durham

Novartis Investigative Site, Marburg

Novartis Investigative Site, Iowa City

Novartis Investigative Site, Rouen

Novartis Investigative Site, Freiburg im Breisgau

Novartis Investigative Site, Vienna

Novartis Investigative Site, Dresden

Novartis Investigative Site, Shinjuku-ku